Sonya M. Hanson

Sonya M. Hanson

Auto-generated profile, based on publicly available information

Sonya M. Hanson

Center for Computational Biology, Flatiron Institute

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2024 in Current Opinion in Structural Biology
Verified
Journal Article
Open access
MAMiro A. Astore
Miro A. Astore
APAkshada S. Pradhan
Akshada S. Pradhan
ETErik H. Thiede
Erik H. Thiede
SHSonya M. Hanson
Sonya M. Hanson
Allostery is the mechanism by which information and control are propagated in biomolecules. It regulates ligand binding, chemical reactions, and conformational changes. An increasing level of experimental resolution and control over allosteric mechanisms promises a deeper understanding of the molecular basis for life and powerful new therapeutics. In this review, we survey the literature for an up-to-date biological and theoretical understanding of protein allostery. By delineating five ways in which the energy landscape or the kinetics of a system may change to give rise to allostery, we aim to help the reader grasp its physical origins. To illustrate this framework, we examine three systems that display these forms of allostery: allosteric inhibitors of beta-lactamases, thermosensation of TRP channels, and the role of kinetic allostery in the function of kinases. Finally, we summarize the growing power of computational tools available to investigate the different forms of allostery presented in this review.

21 February 2018 in eLife
Verified
Journal Article
Open access
EREmily F Ruff
Emily F Ruff
JMJoseph M Muretta
Joseph M Muretta
ATAndrew R Thompson
Andrew R Thompson
ELEric W Lake
Eric W Lake
SCSoreen Cyphers
Soreen Cyphers
NLNicholas M Levinson
Nicholas M Levinson
Many eukaryotic protein kinases are activated by phosphorylation on a specific conserved residue in the regulatory activation loop, a post-translational modification thought to stabilize the active DFG-In state of the catalytic domain. Here we use a battery of spectroscopic methods that track different catalytic elements of the kinase domain to show that the ~100 fold activation of the mitotic kinase Aurora A (AurA) by phosphorylation occurs without a population shift from the DFG-Out to the DFG-In state, and that the activation loop of the activated kinase remains highly dynamic. Instead, molecular dynamics simulations and electron paramagnetic resonance experiments show that phosphorylation triggers a switch within the DFG-In subpopulation from an autoinhibited DFG-In substate to an active DFG-In substate, leading to catalytic activation. This mechanism raises new questions about the functional role of the DFG-Out state in protein kinases.

13 May 2016 in eLife
Verified
Journal Article
Open access
FZFeng Zhang
Feng Zhang
SHSonya M Hanson
Sonya M Hanson
AJAndres Jara-Oseguera
Andres Jara-Oseguera
DKDmitriy Krepkiy
Dmitriy Krepkiy
CBChanhyung Bae
Chanhyung Bae
KSKenton J Swartz
Kenton J Swartz
The TRPV1 channel is a detector of noxious stimuli, including heat, acidosis, vanilloid compounds and lipids. The gating mechanisms of the related TRPV2 channel are poorly understood because selective high affinity ligands are not available, and the threshold for heat activation is extremely high (>50°C). Cryo-EM structures of TRPV1 and TRPV2 reveal that they adopt similar structures, and identify a putative vanilloid binding pocket near the internal side of TRPV1. Here we use biochemical and electrophysiological approaches to investigate the resiniferatoxin(RTx) binding site in TRPV1 and to explore the functional relationships between TRPV1 and TRPV2. Collectively, our results support the interaction of vanilloids with the proposed RTx binding pocket, and demonstrate an allosteric influence of a tarantula toxin on vanilloid binding. Moreover, we show that sensitivity to RTx can be engineered into TRPV2, demonstrating that the gating and permeation properties of this channel are similar to TRPV1.

9 June 2023 in The Journal of Physical Chemistry B
Verified
Journal Article
Closed access
WTWai Shing Tang
Wai Shing Tang
DSDavid Silva-Sánchez
David Silva-Sánchez
JGJulian Giraldo-Barreto
Julian Giraldo-Barreto
BCBob Carpenter
Bob Carpenter
SHSonya M. Hanson
Sonya M. Hanson
Pilar CossioPilar Cossio
Pilar Cossio

13 July 2018 in Biochemistry
Verified
Journal Article
Closed access
SASteven K. Albanese
Steven K. Albanese
DPDaniel L. Parton
Daniel L. Parton
MIMehtap Işık
Mehtap Işık
LRLucelenie Rodríguez-Laureano
Lucelenie Rodríguez-Laureano
SHSonya M. Hanson
Sonya M. Hanson
JCJohn Chodera
John Chodera

29 February 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
YIYuma Ishigami
Yuma Ishigami
MWMandy S. Wong
Mandy S. Wong
CMCarlos Martí-Gómez
Carlos Martí-Gómez
AAAndalus Ayaz
Andalus Ayaz
MKMahdi Kooshkbaghi
Mahdi Kooshkbaghi
JKJustin B. Kinney
Justin B. Kinney
Drugs that target pre-mRNA splicing hold great therapeutic potential, but the quantitative understanding of how these drugs work is limited. Here we introduce mechanistically interpretable quantitative models for the sequence-specific and concentration-dependent behavior of splice-modifying drugs. Using massively parallel splicing assays, RNA-seq experiments, and precision dose-response curves, we obtain quantitative models for two small-molecule drugs, risdiplam and branaplam, developed for treating spinal muscular atrophy. The results quantitatively characterize the specificities of risdiplam and branaplam for 5’ splice site sequences, suggest that branaplam recognizes 5’ splice sites via two distinct interaction modes, and contradict the prevailing two-site hypothesis for risdiplam activity at SMN2 exon 7. The results also show that anomalous single-drug cooperativity, as well as multi-drug synergy, are widespread among small-molecule drugs and antisense-oligonucleotide drugs that promote exon inclusion. Our quantitative models thus clarify the mechanisms of existing treatments and provide a basis for the rational development of new therapies.